[1]陈全军,高燕燕,李莉,等.肠促胰素类药物对2型糖尿病病人淀粉酶活性影响[J].齐鲁医学杂志,2017,32(03):348-,350,354.[doi:10.13362/j.qlyx.201703032]
 CHEN Quanjun,GAO Yanyan,LI Li,et al. EFFECTS OF INCRETIN-BASED DRUGS ON AMYLASE ACTIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS[J].Medical Journal of Qilu,2017,32(03):348-,350,354.[doi:10.13362/j.qlyx.201703032]
点击复制

肠促胰素类药物对2型糖尿病病人淀粉酶活性影响()
分享到:

《齐鲁医学杂志》[ISSN:1008-0341/CN:37-1280/R]

卷:
第32卷
期数:
2017年03期
页码:
348-,350,354
栏目:
出版日期:
2017-08-07

文章信息/Info

Title:
 EFFECTS OF INCRETIN-BASED DRUGS ON AMYLASE ACTIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
文章编号:
1008-0341(2017)03-0348-04
作者:
陈全军12高燕燕1李莉1咸玉欣1王静1牛佳鹏1
1 青岛大学附属医院内分泌科,山东 青岛 266100; 2 青岛市崂山区社区卫生服务中心
Author(s):
CHEN Quanjun GAO Yanyan LI Li XIAN Yuxin WANG Jing NIU Jiapeng
Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao 266100, China
关键词:
肠促胰岛素类糖尿病2型淀粉酶三酰甘油类人体质量指数
Keywords:
 incretins diabetes mellitus type 2 amylase triglyceride body mass index
分类号:
R587.1
DOI:
10.13362/j.qlyx.201703032
文献标志码:
A
摘要:
目的 探讨肠促胰素类药物对2型糖尿病(T2DM)病人血清淀粉酶(AMY)和尿液淀粉酶(UAMY)活性影响。
方法 选取符合条件的T2DM病人320例,随机分为对照组和观察组各160例。观察组病人应用肠促胰素类药物治疗,根据病情可加用其他降糖药物;对照组病人只应用其他降糖药物治疗。比较两组病人治疗前、治疗12周后的AMY、UAMY和一般生化指标水平,并依据体质量指数(BMI)、三酰甘油(TG)水平对观察组病人AMY及UAMY变化进行分层分析。
结果 治疗前及治疗12周后,两组病人总胆固醇(TC)、TG、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、糖化血红蛋白A1c(HbA1c)、AMY及UAMY水平比较,差异均无统计学意义(P>0.05)。两组病人治疗后TC、LDL、HbA1c水平较治疗前降低,差异有统计学意义(t=3.86~11.62,P<0.05)。观察组病人肠促胰素两类药物治疗者AMY及UAMY水平比较,差异无统计学意义(P>0.05)。依据BMI、TG分层,随层级升高,观察组病人AMY及UAMY水平依次升高,层间差异有统计学意义(F=4.68~12.81,P<0.05)。
结论 肠促胰素类药物一般情况下不会引起T2DM病人淀粉酶活性的变化,但随着病人TG及BMI的升高,可能会引起淀粉酶活性升高,需引起关注。
Abstract:
Objective  To investigate the effects of incretin-based drugs on the activity of serum amylase (AMY) and urinary amylase (UAMY) in patients with type 2 diabetes mellitus (T2DM).
Methods  A total of 320 patients with T2DM who meet the criteria were equally and randomly divided into control group and observation group. The observation group was given hypoglycemic drugs according to the condition in addition to incretin-based drugs, while the control group was given hypoglycemic drugs only. The levels of AMY, UAMY, and other biochemical parameters were compared between the two groups before treatment and after 12 weeks of treatment. The changes in levels of AMY and UAMY in the observation group were analyzed after the patients were stratified by body mass index (BMI) and triglyceride (TG) level.
Results  Before treatment and after 12 weeks of treatment, there were no significant differences in levels of total cholesterol (TC), TG, low-density lipoprotein (LDL), high-density lipoprotein (HDL), glycosylated hemoglobin A1c (HbA1c), AMY, and UAMY between the two groups (P>0.05). Both groups showed significant decreases in levels of TC, LDL, and HbA1c after treatment (t=3.86-11.62,P<0.05). There were no significant differences in levels of AMY and UAMY between the patients who received two types of incretin-based drugs in the observation group after treatment (P>0.05). After the patients in the observation group were stratified by BMI and TG level, there were significant differences in levels of AMY and UAMY between the patients in different stratifications (F=4.68-12.81,P<0.05), with the levels of AMY and UAMY increased with the increases in BMI and TG level.
Conclusion  In general, incretin-based drugs cannot cause the changes in amylase level in patients with T2DM. However, the amylase level may increase with the increases in BMI and TG level, which should be paid attention to.
更新日期/Last Update: 2017-08-12